Physician profile
Trinity Walls
NPI 1053970558
$3,101.13
in general payments reported to CMS, 2019-2025
19 companies · $69.69 in 2025
The $69.69 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $563 · 2022: $1,797 · 2023: $672 · 2025: $69.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $1,158.94 | 2021-2022 | |
| Abbvie INC. | $461.40 | 2021-2023 | |
| Novo Nordisk INC | $312.97 | 2021-2023 | Wegovy |
| Agile Therapeutics, INC. | $257.23 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $165.40 | 2021-2023 | Slynd |
| Sumitomo Pharma America, INC. | $132.13 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $94.26 | 2023-2025 | Myosure Tissue Removal Device, Acessa Provu System, Aptima |
| Astellas Pharma US INC | $88.65 | 2023 | Veozah, Myrbetriq |
| Avion Pharmaceuticals | $84.70 | 2021-2022 | |
| Axonics, INC. | $71.98 | 2022-2023 | Axonics |
| Biohaven Pharmaceuticals, INC. | $57.34 | 2021 | |
| Therapeuticsmd, INC. | $55.32 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $34.77 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.67 | 2022 | |
| Teleflex LLC | $23.55 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $22.17 | 2022 | |
| Evofem Biosciences, INC. | $19.71 | 2022 | |
| Mylan Pharmaceuticals INC. | $18.76 | 2021 | |
| Shield Therapeutics INC | $14.18 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinity Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.